Tauzin: Path Needed For Cures That Spans Financing To Reimbursement

Former PhRMA President and House Energy & Commerce Committee Chair Billy Tauzin says Congress should create a separate path for curative drugs that spans research and development, FDA review and reimbursement. Although FDA's breakthrough-drug program wasn't designed for cures, it could be a good starting point for the review portion of that unique path, the former Louisiana Republican lawmaker tells Inside Health Policy . Tauzin says drug companies were already telling him that curative drugs would not fit into the...